*	Application No.	Applicant(s)	
Notice of Allowability	09/994,012	YU ET AL.	
	Examiner	Art Unit	
	Rebecca L Anderson	1626	
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in or other appropriate commu GHTS. This application is s	this application. If not include inication will be mailed in due	ed course. <b>THIS</b>
1. This communication is responsive to 9 May 2003.			
2. The allowed claim(s) is/are 1, 4-8 and 10, now renumbered 1-7.			
3. The drawings filed on are accepted by the Examine			
4. Acknowledgment is made of a claim for foreign priority und a) All b) Some* c) None of the:		(f).	
1. Certified copies of the priority documents have	been received.		
2. Certified copies of the priority documents have	been received in Application	n No	
3. Copies of the certified copies of the priority do	cuments have been received	I in this national stage applicat	tion from the
International Bureau (PCT Rule 17.2(a)).			
* Certified copies not received:			
5. Acknowledgment is made of a claim for domestic priority un	nder 35 U.S.C. § 119(e) (to a	a provisional application).	
(a) The translation of the foreign language provisional application has been received.			
6. Acknowledgment is made of a claim for domestic priority ur	nder 35 U.S.C. §§ 120 and/o	r 121.	
Applicant has THREE MONTHS FROM THE "MAILING DATE" of below. Failure to timely comply will result in ABANDONMENT of the submitted of the complete of the compl	this application. THIS THRI itted. Note the attached EXA	EE-MONTH PERIOD IS NOT I	EXTENDABLE.
INFORMAL PATENT APPLICATION (PTO-152) which gives reas	on(s) why the oath of declar	ation is delicient.	
<ul> <li>8.  CORRECTED DRAWINGS must be submitted.</li> <li>(a)  including changes required by the Notice of Draftspers</li> <li>1)  hereto or 2)  to Paper No</li> <li>(b)  including changes required by the proposed drawing of including changes required by the attached Examiner'</li> </ul>	correction filed, which	h has been approved by the E	
(b) I moduling changes required by the attached Examiner	s Amendment / Comment of	in the Office action of Laper I	
Identifying indicia such as the application number (see 37 CFR 1. each sheet.	84(c)) should be written on th	e drawings in the front (not the	back) of
9.   DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT FOR TI	sit of BIOLOGICAL MATE HE DEPOSIT OF BIOLOGIC	RIAL must be submitted. N CAL MATERIAL.	lcte the
Attachment(s)			
<ul> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statements (PTO-1449), Paper No</li></ul>	4⊠ Interview 6⊠ Examinei	Informal Patent Application (F Summary (PTO-413), Paper I r's Amendment/Comment r's Statement of Reasons for A	No. <u>0625</u> .

## **DETAILED ACTION**

Page 2

Claims 1, 4-8 and 10 are currently pending in the instant application, are allowable over the prior art of record and are renumbered as claims 1-7. Original claims 2 and 3 were cancelled and claims 1 and 7 were amended in the amendment filed 9 May 2003.

## **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Samuel Duboff on 24 June 2003.

The application has been amended as follows:

- 1. On page 1 of the specification, on the line above "BACKGROUND OF THE INVENTION", insert:
- --This application claims the benefit under 35 USC 119(e) of U.S. Provisional Application 60/257,139 filed December 20, 2000.—
  - 2. Amend claim 10 to read as follows:
- --A pharmaceutical composition which comprises a therapeutically effective amount of one or more of the aforementioned compounds as claimed in any one of claims 1, 4, 5, 6, 7 or 8, and a pharmaceutically acceptable carrier.--

Application/Control Number: 09/994,012

Art Unit: 1626

## Reasons for Allowance

The following is an examiner's statement of reasons for allowance. This invention relates to quinolinone substituted benzimidazole compounds. The novel and nonobvious aspect of this invention involves the quinolinone substituent on the benzimidazole. The closest prior art of record, WO 00/04900, which discloses benzotriazole substituted benzimidazole compounds useful for the treatment of respiratory syncytial virus infection, fails to teach or suggest the substitution of the benzimidazole with a quinolinone substituent.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

## Conclusion

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rebecca L. Anderson whose telephone number is (703) 605-1157. Mrs. Anderson can normally be reached Monday through Friday 7:00AM to 3:30PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Mr. Joseph McKane, can be reached at (703) 308-4537.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone numbers are (703) 308-1235 and (703) 308-0196.

Application/Control Number: 09/994,012

Art Unit: 1626

A facsimile center has been established. The hours of operation are Monday through Friday, 8:45AM to 4:45PM. The telecopier numbers for accessing the facsimile machine are (703) 308-4242, (703) 305-3592, and (703) 305-3014.

Rebecca Anderson Patent Examiner Art Unit 1626, Group 1620 Technology Center 1600 Joseph K. M. K... Joseph McKane Supervisory Patent Examiner Art Unit 1626, Group 1620 Technology Center 1600 Page 4